375 related articles for article (PubMed ID: 7759858)
21. Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport.
Hatch M; Freel RW; Shahinfar S; Vaziri ND
J Pharmacol Exp Ther; 1996 Jan; 276(1):187-93. PubMed ID: 8558429
[TBL] [Abstract][Full Text] [Related]
22. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats.
Stier CT; Adler LA; Levine S; Chander PN
J Hypertens Suppl; 1993 Apr; 11(3):S37-42. PubMed ID: 8315518
[TBL] [Abstract][Full Text] [Related]
23. The advantages of angiotensin II antagonism.
Burnier M; Waeber B; Brunner HR
J Hypertens Suppl; 1994 Jul; 12(2):S7-15. PubMed ID: 7965267
[TBL] [Abstract][Full Text] [Related]
24. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
Dahlöf B
J Hum Hypertens; 1995 Nov; 9 Suppl 5():S37-44. PubMed ID: 8583480
[TBL] [Abstract][Full Text] [Related]
25. Renin-angiotensin blockade improves renal cGMP production via non-AT(2)-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat.
Uhlenius N; Vuolteenaho O; Tikkanen I
J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):233-9. PubMed ID: 11881129
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats.
von Lutterotti N; Camargo MJ; Campbell WG; Mueller FB; Timmermans PB; Sealey JE; Laragh JH
J Hypertens; 1992 Sep; 10(9):949-57. PubMed ID: 1328376
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular and renal protective effects of losartan in spontaneously hypertensive rats with diabetes mellitus.
Kohzuki M; Yasujima M; Liu PF; Obara K; Kanazawa M; Yoshida K; Saito T; Sato T; Abe K
Clin Exp Pharmacol Physiol Suppl; 1995 Dec; 22(1):S366-7. PubMed ID: 9072430
[TBL] [Abstract][Full Text] [Related]
28. Angiotensinogen depletion by high renin levels in hypertensive rats: no evidence for tonic stimulation of angiotensinogen by angiotensin II.
Gahnem F; Camargo MJ; von Lutterotti N; Laragh JH; Sealey JE
J Hypertens; 1995 Jan; 13(1):91-6. PubMed ID: 7759857
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content.
Smits JF; van Krimpen C; Schoemaker RG; Cleutjens JP; Daemen MJ
J Cardiovasc Pharmacol; 1992; 20(5):772-8. PubMed ID: 1280740
[TBL] [Abstract][Full Text] [Related]
30. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent.
Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1990 Feb; 252(2):726-32. PubMed ID: 2179532
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin II receptor antagonist losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: lack of relation to vascular structure.
Morton JJ; Beattie EC; MacPherson F
J Vasc Res; 1992; 29(3):264-9. PubMed ID: 1387008
[TBL] [Abstract][Full Text] [Related]
32. Effects of angiotensin II on insulin receptor binding and mRNA levels in normal and diabetic rats.
Sechi LA; Griffin CA; Zingaro L; Valentin JP; Bartoli E; Schambelan M
Diabetologia; 1997 Jul; 40(7):770-7. PubMed ID: 9243097
[TBL] [Abstract][Full Text] [Related]
33. Effects of Losartan, a nonpeptide angiotensin II receptor antagonist, on norepinephrine overflow and antidiuresis induced by stimulation of renal nerves in anesthetized dogs.
Suzuki Y; Matsumura Y; Egi Y; Morimoto S
J Pharmacol Exp Ther; 1992 Dec; 263(3):956-63. PubMed ID: 1469652
[TBL] [Abstract][Full Text] [Related]
34. Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats.
Spence SG; Allen HL; Cukierski MA; Manson JM; Robertson RT; Eydelloth RS
Teratology; 1995 Jun; 51(6):367-82. PubMed ID: 7502237
[TBL] [Abstract][Full Text] [Related]
35. Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension and diabetes.
Rumble JR; Doyle AE; Cooper ME
Am J Hypertens; 1995 Jan; 8(1):53-7. PubMed ID: 7734098
[TBL] [Abstract][Full Text] [Related]
36. Chronic effect of losartan in a murine model of dilated cardiomyopathy: comparison with captopril.
Kanda T; Araki M; Nakano M; Imai S; Suzuki T; Murata K; Kobayashi I
J Pharmacol Exp Ther; 1995 May; 273(2):955-8. PubMed ID: 7752100
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes.
Lee EY; Shim MS; Kim MJ; Hong SY; Shin YG; Chung CH
Exp Mol Med; 2004 Feb; 36(1):65-70. PubMed ID: 15031673
[TBL] [Abstract][Full Text] [Related]
38. Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade.
Camargo MJ; von Lutterotti N; Campbell WG; Pecker MS; James GD; Timmermans PB; Laragh JH
J Hypertens; 1993 Jan; 11(1):31-40. PubMed ID: 8382237
[TBL] [Abstract][Full Text] [Related]
39. Renal effects of an angiotensin II antagonist in stroke-prone spontaneously hypertensive rat.
Yo Y; Moriguchi A; Higaki J; Nagano M; Nakano N; Kamide K; Yu H; Mikami H; Ogihara T
Nephron; 1997; 76(4):466-71. PubMed ID: 9274845
[TBL] [Abstract][Full Text] [Related]
40. Antihypertensive mechanism of captopril in renal hypertensive rats: studies with a nonpeptide angiotensin II receptor antagonist and an angiotensin II monoclonal antibody.
Wong PC; Price WA; Reilly TM; Duncia JV; Timmermans PB
J Pharmacol Exp Ther; 1989 Aug; 250(2):515-22. PubMed ID: 2668502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
